For research and educational purposes only. Not medical advice.

Degarelix Reference

Educational, not medical advice reference for Degarelix: Reproductive, Hormonal; regulatory status, evidence posture, source review, and schedul…

Reference summary

Degarelix is a label-verified GnRH antagonist depot with a Phase 3 head-to-head (CS21) against leuprolide showing comparable testosterone suppression by day 28, faster onset (suppression within days), and absence of the testosterone microsurge / clinical flare that GnRH agonists produce in the first 1 to 2 weeks. pepSmart surfaces label-reference content only.

Regulatory and posture

Categories
Reproductive, Hormonal
Aliases
Firmagon, GnRH antagonist, GnRH antagonist depot, Degarelix acetate, FE200486
Evidence posture
human - Oncology drug. Prescription-only and clinician-administered; off-label or self-administered use is not safe and is outside FDA approval. Prolonged androgen-deprivation therapy carries bone-density loss, cardiovascular events, hot flashes, libido loss, ALT/AST elevations, and label-noted QT/QTc considerations in at-risk patients.
Regulatory status
FDA-approved prescription medication (Firmagon). Indicated for advanced prostate cancer. Prescription-only and clinician-administered. EU- and Japan-approved with the same indication.
Content review status
label verified

Selected public sources

Related tools